Last updated on March 2020

A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic in Adults With Schizophrenia as Measured Positron Emission Tomography (PET) Imaging


Brief description of study

A clinical study to investigate the effect of an investigational drug as an added medication to an antipsychotic, in adults with schizophrenia, as measured positron emission tomography (PET) imaging . This study is accepting male and female participants between 18 years old -45 years old who have been diagnosed with schizophrenia. This study will be conducted in 2 locations in the UK. The study will last approximately 14 months.

Detailed Study Description

This is a single-site, open-label, flexibly-dosed study evaluating the effect on brain dopamine synthesis capacity as measured by 18F-DOPA PET imaging of adjunctive open-label administration of SEP-363856 (50 to 75 mg/day) over 2 weeks in adults with schizophrenia. The study will consist of 3 periods: Screening (up to 28 days), Treatment (2 weeks), and a Follow-up visit

Clinical Study Identifier: NCT04038957

Find a site near you

Start Over

King's College London

London, United Kingdom
  Connect »